High incidence of mental disorders, reduced mental well‐being and cognitive function in hypopituitary women with GH deficiency treated for pituitary disease

Bülow, Birgitta; Hagmar, Lars; Ørbæk, Palle; Österberg, Kai; Erfurth, Eva Marie

doi:10.1046/j.0300-0664.2001.01461.x

Cited by 72 publications

(62 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 18 months of GH replacement therapy, no significant improvements in cognitive performance were found in the GH-treated patients when compared with the placebo group (29). By contrast, Bü low et al The patients scored significantly lower on four of the seven tests, namely tests of vocabulary, perceptual speed, spatial and learning speed and one of the tests measuring reaction time (30). As the authors suggest, several others factors, such as transfrontal surgery, radiotherapy, visual impairments or suboptimal hormonal substitution, might have negatively affected the disturbances in cognitive function found in this study.…”

Section: Cognition In Adults With Ao-ghdmentioning

confidence: 88%

Cognition in the adult with childhood-onset GH deficiency

Nieuwpoort

Drent

2008

European Journal of Endocrinology

View full text Add to dashboard Cite

The GH/IGF1 axis may play an important role in cognitive function. This theory is supported by the finding that both GH and IGF1 receptors are located in several brain areas such as the hippocampus, a brain area that is known to play an essential role in cognitive processes, especially memory and learning. However, the exact mechanism by which the GH/IGF1 axis influences the cognitive functions is still unknown. Furthermore, little is known about the cognition in adults with both childhood-onset and adult-onset GH deficiency (CO-GHD and AO-GHD). Recent data indicate that cognitive function, particularly attention and memory, in adults with GHD might be impaired. To date, only a limited number of studies have been conducted to study the effects of GH replacement therapy on cognitive function in adults with GHD. In this paper, the results of studies on cognitive functioning in GHD patients, in particular the results of the studies performed in adults with CO-GHD, and the effects of GH replacement therapy in these patients, will be discussed. European Journal of Endocrinology 159 S53-S57

show abstract

Section: Cognition In Adults With Ao-ghdmentioning

confidence: 88%

Cognition in the adult with childhood-onset GH deficiency

Nieuwpoort

Drent

2008

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Additionally, reduced self-confidence, disturbed sex life (6), decreased physical mobility (4), dissatisfaction with body image (9), poor memory (10), reduced cognitive function and decreased mood (11), as well as attention deficits (12) have also been reported. A higher incidence of mental disorders, more pronouncedly expressed mental distress and relatively frequent cognitive dysfunctions complete this picture (13). The majority of these findings originate from early studies that were performed in relatively small patient cohorts followed for a limited period.…”

Section: Introductionmentioning

confidence: 87%

Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations

Kołtowska-Häggström¹,

Mattsson²,

Shalet³

2009

European Journal of Endocrinology

View full text Add to dashboard Cite

Quality of life (QoL) has emerged as an important construct that has found numerous applications across healthcare-related fields, ranging from research and clinical evaluation of treatment effects to pharmacoeconomic evaluations and global healthcare policy. Impairment of QoL is one of the key clinical characteristics in adult GHD and has been extensively studied in the Pfizer International Metabolic Database (KIMS). We provide summarized evidence on GH treatment effects for both clinical and health economic applications based on the KIMS data. The primary focus is on those aspects of QoL research that cannot be investigated in the traditional clinical trial setting, such as specific patient subgroups, cross-country comparisons and long-term follow-up. First, the impact of age, gender, disease onset, primary aetiology, extent of hypopituitarism, previous radiotherapy and obesity on QoL before and during long-term GH replacement is discussed. Secondly, the studies on QoL in relation to country-specific normative values are reviewed. Finally, health economic data derived from KIMS including both burden of disease and utility assessment are evaluated. We conclude that the wide spectrum of analyses performed on the KIMS data allows for practical application of the results not only to research and clinical practice but also to health policy and global medical decision making.

show abstract

“…[3][4][5][6][7][8] If these observations are translated to the human situation, we would anticipate that both in aged humans and in GH/IGF-Ideficient subjects, the number of hippocampal GABAergic and glutamatergic synapses may be imbalanced as compared to young and healthy individuals, which in turn may relate to cognitive disturbances known to occur in both cases. 4,9 This possibility warrants further study.…”

Section: Discussionmentioning

confidence: 99%